Overview
NICE is unable to make a recommendation on tisagenlecleucel (Kymriah) for treating relapsed or refractory follicular lymphoma in adults after 2 or more therapies. This is because Novartis did not provide an evidence submission.
Last reviewed: 22 November 2022
Next review: We will review this decision if the company decides to make a submission.